Ploug M, Ostergaard S, Hansen L B, Holm A, Danø K
Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
Biochemistry. 1998 Mar 17;37(11):3612-22. doi: 10.1021/bi972787k.
Binding of urokinase-type plasminogen activator (uPA) to its cellular receptor (uPAR) renders the cell surface a favored site for plasminogen activation. Recently, a 15-mer peptide antagonist of the uPA-uPAR interaction, with an IC50 value of 10 nM, was identified using phage display technology [Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) Proc. Natl. Acad. Sci. 91, 7129-7133]. In the present study, the molecular aspects of the interaction between this peptide and uPAR have been investigated. We have characterized the real-time receptor binding kinetics for the antagonist using surface plasmon resonance and identified critical residues by alanine replacements. The minimal peptide antagonist thus derived (SLNFSQYLWS) was rendered photoactivatable by replacing residues important for uPAR binding with photochemically active derivatives of phenylalanine containing either (trifluoromethyl)diazirine or benzophenone. These peptides incorporated covalently into purified soluble uPAR upon photoactivation, and this was inhibited by preincubation with receptor binding derivatives of uPA. The intact three-domain structure of uPAR was essential for efficient photoaffinity labeling. Proteolytic domain mapping using chymotrypsin revealed a specific labeling of both uPAR domain I and domains II + III dependent on the position of the photoprobe in the antagonist. On the basis of these studies, we propose the existence of a composite ligand binding site in uPAR combined of residues located in distinct structural domains. According to this model, a close spatial proximity between uPAR domain I and either domains II or III in intact uPAR is required for the assembly of this composite binding site. Since the receptor binding properties of the peptide antagonist closely mimic those of uPA itself, these two ligands presumably share coincident binding site in uPAR.
尿激酶型纤溶酶原激活剂(uPA)与其细胞受体(uPAR)的结合使细胞表面成为纤溶酶原激活的有利位点。最近,利用噬菌体展示技术鉴定出一种uPA-uPAR相互作用的15聚体肽拮抗剂,其IC50值为10 nM [古德森,R. J.,多伊尔,M. V.,考夫曼,S. E.,和罗森伯格,S.(1994年)《美国国家科学院院刊》91,7129 - 7133]。在本研究中,对该肽与uPAR之间相互作用的分子层面进行了研究。我们利用表面等离子体共振表征了拮抗剂的实时受体结合动力学,并通过丙氨酸替代鉴定了关键残基。通过用含(三氟甲基)二氮杂环丙烷或二苯甲酮的苯丙氨酸光化学活性衍生物替代对uPAR结合重要的残基,使由此得到的最小肽拮抗剂具有光活性。这些肽在光激活后共价结合到纯化的可溶性uPAR中,并且通过与uPA的受体结合衍生物预孵育可抑制这种结合。uPAR完整的三结构域结构对于有效的光亲和标记至关重要。使用胰凝乳蛋白酶进行的蛋白水解结构域图谱分析显示,uPAR结构域I以及结构域II + III的特异性标记取决于拮抗剂中光探针的位置。基于这些研究,我们提出在uPAR中存在一个由位于不同结构域的残基组成的复合配体结合位点。根据该模型,完整uPAR中uPAR结构域I与结构域II或结构域III之间紧密的空间接近度是该复合结合位点组装所必需的。由于肽拮抗剂的受体结合特性与uPA本身非常相似,这两种配体可能在uPAR中共享重合的结合位点。